^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    luveltamab tazevibulin (STRO-002)

    i
    Company:
    Sutro Biopharma, Tasly
    Drug class:
    Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate
    Related drugs:
    Apply
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (NCT05870748)
    Phase 2/3
    Sutro Biopharma, Inc.
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2025
    Completion :
    02/01/2026
    FOLR1
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)